AUSTRALIAN CANCER CARE NETWORK LAUNCHES TO LINK SERVICES TO POPULATION, CLINICIANS & RESEARCHERS
Aims to reduce health system disparities and tackle cancers with low survival rates
The landscape of cancer care in Australia is set to transform with the Australian Government launch in May 2024 of the Australian Comprehensive Cancer Network (ACCN) at the Innovations Showcase event, hosted by Cancer Australia in Sydney, Australia.
The ACCN is a nationally integrated system of cancer care, aimed at enhancing patient experiences and outcomes through coordinated and equitable access, by linking to comprehensive cancer services across Australia. Anchored by Comprehensive Cancer Centres (CCCs), the ACCN strives to deliver evidence-driven prevention, diagnosis, treatment, and support to all Australians affected by cancer.
Comprehensive Cancer Centres (CCCs) will serve as anchors in the ACCN, connecting various cancer control services nationwide. Through building partnerships and harnessing virtual connectivity, CCCs will collaborate with other cancer care centres, academic institutions, Aboriginal Community Controlled Health Services, regional hospitals and allied health services, among others.
While Australia has some of the world’s highest cancer survival rates, not all people experience equal outcomes. There are significant disparities in cancer outcomes for some populations, particularly affecting those in rural and remote regions, as well as Aboriginal and Torres Strait Islander communities.
The ACCN aims to address these disparities, emphasising coordinated and equitable access to comprehensive cancer services irrespective of where a person lives, and marking a significant milestone in the advancement of cancer care in Australia.
Australian Health Journal spoke with Professor Dorothy Keefe CEO, Cancer Australia on the ACCN launch and the network being a major milestone in the Australian Cancer Plan, which was launched at the end of 2023.
Participation in the ACCN is voluntary, with services committing to a set of standards focusing on comprehensive cancer care, equitable access, research excellence, data collection, workforce development, and network connectivity. Importantly, the ACCN will complement existing networks and alliances within the cancer care landscape, fostering collaboration and maximising resources.
All services and professionals involved in cancer care are encouraged to join the ACCN and contribute to this transformative initiative.
“As part of the implementation of the Australian Cancer Plan launched in November, the ACCN represents an essential stage towards achieving our goals of improving cancer outcomes and experiences for all Australians.”, says Professor Keefe.
She points out, “To achieve world class cancer outcomes for all Australians and realise the ambition of the Australian Cancer Plan, we need collective action from all sectors of health care to address issues that contribute to variation in cancer outcomes and experience.”
-
Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
-
Stroke care advances in translated research
New nurse-led protocols for stroke patients, based on ACU research, led by the Nursing Research Institute, have resulted in changes to policy, guidelines and clinical practice in Europe and Australia. The protocols were developed through the Quality in Acute Stroke Care (QASC) Trial (published in the Lancet, 2011) to manage fever, hyperglycaemia and swallowing (FeSS) post-stroke.
-
Interventional radiologists offer alternative to hysterectomy
In Australia in the last five years, an estimated 6066 women per year have undergone hysterectomies to treat fibroid-related diseases, while just 145 women each year have undergone a uterine artery embolisation, or UAE.
The procedure can effectively treat the majority of bleeding uterine fibroids. Each year, thousands of Australian women undergo invasive and life-altering hysterectomies to treat debilitating pain and blood loss caused by uterine fibroids. But there’s another option: a minimally invasive, pin-hole procedure that treats the symptoms, yet leaves the uterus intact.
